<DOC>
	<DOCNO>NCT01228279</DOCNO>
	<brief_summary>Hypothesis : Patients start peritoneal dialysis glucose-based regimen high sympathetic activity response increase leptin insulin . Converting patient regimen glucose contain dialysate regimen non-glucose-based solution , icodextrin , reduce insulin leptin level reverse dialysis-induced increase sympathetic activity .</brief_summary>
	<brief_title>Sympathetic Activity Patients With End-stage Renal Disease Peritoneal Dialysis</brief_title>
	<detailed_description>Cardiovascular mortality remain high among patient treat peritoneal dialysis compare patient treated hemodialysis . Sympathetic hyperactivity consider significant emerge risk factor cardiovascular mortality among patient ESRD ( End-Stage Renal Disease ) . Sympathetic activity , via hemodynamic effect trophic effect , interaction RAAS ( Renin Angiotensin Aldosterone System ) , play major role cardiac vascular remodelling , development LVH vascular hypertrophy , well progression CHF . Glucose-based dialysate induces hyperinsulinemia hyperleptinemia . We propose hyperleptinemia induced glucose-based peritoneal solution significant contribute factor sympathetic hyperactivity ESRD patient treat PD , could prevent non-glucose-based PD solution icodextrin-based . Adult patient ESRD start PD first renal replacement therapy modality study . Patients recruit 1-3 week prior start PD treatment . At baseline , specific study microneurography ( MSNA ) , fast plasma insulin , leptin , catecholamine brain natriuretic peptide ( BNP ) perform . EKG record digitize assessment heart rate variability use power spectral analysis . Extracellular fluid volume status assess bioelectrical impedance . Central vascular volume assess inferior vena cava ( IVC ) heart ultrasound . Consequently 24-h ambulatory blood pressure monitoring ( ABPM ) 24-h urine collection urea clearance creatinine clearance do . All participant study receive PD treatment 6 week standard glucose-based PD solution Dianeal . The specific study repeat 6 weeks.Then , patient randomize one two group ( arm ) . One group continue Dianeal PD solution another 12 week . The group receive Dianeal day Extraneal , icodextrin non-glucose base solution , night , next 12 week . The specific study repeat 12 week randomization ( 18 week PD treatment ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Icodextrin</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>Adult ( age 18 year old ) Patients endstage renal disease ( ESRD ) /chronic kidney disease ( CKD ) stage 5 Diabetes Mellitus Acute coronary syndrome past 6 month Cardiac arrhythmia ( 2nd 3rd degree heart block premature ventricular complex Lown class 4 5 ) Symptoms suggestive obstructive central sleep apnea ( score &gt; 10 Epworth sleepiness scale ) Patients take Clonidine Body mass index ( BMI ) &gt; 34 Patients unable give consent Pregnant woman Patients leg injury involve nerve damage Patients take anticoagulant medication Patients significant bleed disorder liver disorder Hemoglobin &lt; 1.05 g/dl time initiation therapy patient unilateral bilateral nephrectomy Planned kidney transplant next 4 month Life expectancy 6 month Oliguria ( urine output le 400 ml per day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Peritoneal Dialysis</keyword>
	<keyword>Dialysis Solutions</keyword>
	<keyword>Artificial Kidney</keyword>
	<keyword>Renal Replacement Therapy</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Sympathetic Nervous System</keyword>
	<keyword>Leptin</keyword>
	<keyword>Icodextrin</keyword>
</DOC>